Concert Pharmaceuticals Inc (CNCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH137836D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

November 2018

Total pages

44

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Concert Pharmaceuticals Inc (Concert Pharmaceuticals) is a clinical stage biotechnology company which discovers and develops small molecule drugs. The company develops its products using its deuterated chemical entity (DCE) platform to develop novel therapeutics for autoimmune and inflammatory diseases, pulmonary diseases, and disorders of central nervous system (CNS). Its product pipeline includes CTP-543 (deuterated ruxolitinib) for alopecia areata; AVP-786 (deuterated dextromethorphan) indicated for alzheimer's agitation, major depressive disorder and residual schizophrenia; CTP-730 (deuterated apremilast) for inflammatory diseases; CTP-692, a selective DCE modified analog of the endogenous amino acid, D-serine for Schizophrenia, and JZP-386 (deuterated sodium-oxybate) for narcolepsy. It employs its deuterated compounds to reduce the extent of metabolism in the wall of the intestines and in the liver. Concert Pharmaceuticals is headquartered in Lexington, Massachusetts, the US.

Concert Pharmaceuticals Inc (CNCE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Concert Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Concert Pharma Raises USD30 Million in Venture Debt Financing 10

Partnerships 11

Concert Pharma Enters Into Co-Development Agreement With Celgene 11

Concert Pharma Enters Into Co-Development Agreement With Fast Forward For C-21191 12

Licensing Agreements 13

Processa Pharma Enters into Licensing Agreement with Concert Pharma 13

Processa Pharma Enters into Option Licensing Agreement with Concert Pharma 14

Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 15

Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 17

Equity Offering 19

Concert Pharma Files Shelf Registration Statement with SEC to Raise USD250 Million 19

Concert Pharma Raises USD50 Million in Public Offering of Shares 20

Concert Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For USD 93 Million 22

Asset Transactions 24

Vertex Pharma Acquires CTP-656 from Concert Pharma 24

Concert Pharmaceuticals Inc-Key Competitors 26

Concert Pharmaceuticals Inc-Key Employees 27

Concert Pharmaceuticals Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Nov 01, 2018: Concert Pharmaceuticals reports third quarter 2018 financial results and provides company update 29

Aug 02, 2018: Concert Pharmaceuticals reports second quarter 2018 financial results and provides company update 30

May 03, 2018: Concert Pharmaceuticals Reports First Quarter 2018 Financial Results 31

Mar 01, 2018: Concert Pharmaceuticals Reports Year Ended 2017 Financial Results 33

Nov 09, 2017: Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update 34

Aug 08, 2017: Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update 35

May 02, 2017: Concert Pharmaceuticals Reports First Quarter 2017 Financial Results 37

Mar 06, 2017: Concert Pharmaceuticals Reports Year Ended 2016 Financial Results 38

Corporate Communications 40

Dec 18, 2017: Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer 40

Dec 13, 2017: Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index 41

May 30, 2017: Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws 42

Product News 43

02/28/2018: Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List of Figure

List of Figures

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List of Table

List of Tables

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Concert Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Concert Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Concert Pharma Raises USD30 Million in Venture Debt Financing 10

Concert Pharma Enters Into Co-Development Agreement With Celgene 11

Concert Pharma Enters Into Co-Development Agreement With Fast Forward For C-21191 12

Processa Pharma Enters into Licensing Agreement with Concert Pharma 13

Processa Pharma Enters into Option Licensing Agreement with Concert Pharma 14

Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 15

Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 17

Concert Pharma Files Shelf Registration Statement with SEC to Raise USD250 Million 19

Concert Pharma Raises USD50 Million in Public Offering of Shares 20

Concert Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For USD 93 Million 22

Vertex Pharma Acquires CTP-656 from Concert Pharma 24

Concert Pharmaceuticals Inc, Key Competitors 26

Concert Pharmaceuticals Inc, Key Employees 27

Concert Pharmaceuticals Inc, Subsidiaries 28

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022